Dyne Therapeutics reports larger-than-expected Q2 net loss per share
Dyne Therapeutics reports larger-than-expected Q2 net loss per share
Overview
U.S. neuromuscular drug developer's Q2 net loss per share was larger than analyst expectations
R&D and G&A expenses rose on higher manufacturing, clinical costs and launch preparations
Company completed $431 mln public offering; expects cash runway into Q2 2028
Outlook
Dyne expects potential U.S. launch of z-rostudirsen in Q1 2027, pending FDA approval
Company plans topline data for z-basivarsen ACHIEVE trial in Q1 2027
Dyne projects cash runway into Q2 2028
Result Drivers
HIGHER CLINICAL COSTS - Co said increased R&D expenses were mainly due to higher manufacturing activity and clinical costs for z-rostudirsen and z-basivarsen
LAUNCH PREPARATIONS - Co attributed higher G&A expenses to increased costs in preparation for the potential launch of z-rostudirsen
Company press release: ID:nGNXbG6Ps4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Miss | -$1.08 | -$0.75 (15 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Dyne Therapeutics, Inc is $40.00, about 54.4% above its July 28 closing price of $25.90
Reuters Recommended Reads
July 29 - FDA panel votes against Capricor's Duchenne heart disease therapy
July 27 - Sarepta names former Abbvie president as CEO as Ingram retires
July 29 - Viking Therapeutics reports Q2 milder-than-expected net loss as obesity trials advance
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)